Visgeneer - Asset Resilience Ratio
Visgeneer (4197) has an Asset Resilience Ratio of 1.34% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Visgeneer (4197) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2021)
This chart shows how Visgeneer's Asset Resilience Ratio has changed over time. See Visgeneer book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Visgeneer's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Visgeneer market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$5.80 Million | 1.34% |
| Total Liquid Assets | NT$5.80 Million | 1.34% |
Asset Resilience Insights
- Limited Liquidity: Visgeneer maintains only 1.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Visgeneer Industry Peers by Asset Resilience Ratio
Compare Visgeneer's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Visgeneer (2013–2021)
The table below shows the annual Asset Resilience Ratio data for Visgeneer.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 1.36% | NT$5.80 Million ≈ $182.73K |
NT$427.04 Million ≈ $13.45 Million |
-8.53pp |
| 2020-12-31 | 9.89% | NT$45.67 Million ≈ $1.44 Million |
NT$461.96 Million ≈ $14.55 Million |
+8.68pp |
| 2019-12-31 | 1.21% | NT$5.80 Million ≈ $182.73K |
NT$480.76 Million ≈ $15.15 Million |
-0.08pp |
| 2018-12-31 | 1.29% | NT$5.80 Million ≈ $182.73K |
NT$451.24 Million ≈ $14.22 Million |
-0.79pp |
| 2013-12-31 | 2.08% | NT$6.90 Million ≈ $217.39K |
NT$332.39 Million ≈ $10.47 Million |
-- |
About Visgeneer
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cr… Read more